Sherry C. on
Monday, May 23rd, 2016
Despite many encouraging leads, new Alzheimer’s Treatment is “slow to emerge,”according to Mayo Clinic. The good news is that as time progresses, a better understanding of how Alzheimer’s affects the brain has given scientists more of a clear understanding of new ways to implement effective treatment of the disease. Continue reading to learn more about Mayo Clinic’s report regarding some of these promising new research studies.
Sherry C. on
Sunday, November 23rd, 2014
The International Conference on Clinical Trials for Alzheimer’s Disease in Philadelphia, (also referred to as the CTAD) recently met to gather information regarding current research initiatives showing the most promise for Alzheimer’s treatment and prevention.
The CTAD began in 2008 and since that time has continued its function to provide a platform for professional research experts from around the globe to come together in collaboration regarding research that may lead to new intervention and prevention modalities for AD. The disease effects 5.4 million people in American and nearly 36 million (with AD and related dementias) world-wide-and by the year 2050 that number is expected to grow to an astounding 115 million. In fact, if successful intervention is not achieved in the next 35 years, many experts project that Alzheimer’s disease may cost more than any other major illness in the healthcare industry-worldwide.
Top researchers around the globe came together for this year’s conference to discuss Alzheimer’s treatment and AD prevention and treatment clinical research trials that exhibit the most hope for the future. Other topics of discussion included-a strategy for new treatment alternatives for mild to moderate Alzheimer’s disease, as well as new drug treatment for some of the most disconcerting symptoms of the disease.
The conference was chaired by Paul Aisen, MD, University of California at San Diego; Bruno Vellas, MD, University of Toulouse; Jacques Touchon, MD, University of Montpellier; and Michael Weiner, MD, University of California at San Francisco.
According to the director of the Alzheimer’s Disease Cooperative Study (and Co-Organizer of the CTAD Conference), Paul Aisen, MD: “As evidenced by the research being presented this year, efforts to develop effective treatments for Alzheimer’s disease have been focused on the earliest stages of the disease, before symptoms are even apparent—but the needs of people already diagnosed have not been forgotten.”
The following topics discussed at the conference will be covered in subsequent blog entries:
Preventing Alzheimer’s By Treating Early
New Alzheimer’s Treatment Strategies for Mild to Moderate AD
Treating the most troubling symptoms in AD